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Background: Acute kidney injury (AKI) is associated with significant short-term morbidity and mortality in children.
However, the risk for long-term outcomes after AKI is largely unknown.
Methods: We performed a systematic review and meta-analysis to determine the cumulative incidence rate of
proteinuria, hypertension, decline in glomerular filtration rate (GFR), and mortality after an episode of AKI. After screening
1934 published articles from 1985–2013, we included 10 cohort studies that reported long-term outcomes after AKI in
children.
Results: A total of 346 patients were included in these studies with a mean follow-up of 6.5 years (range 2–16) after AKI.
The studies were of variable quality and had differing definitions of AKI with five studies only including patients who
required dialysis during an AKI episode. There was a substantial discrepancy in the outcomes across these studies, most
likely due to study size, disparate outcome definitions, and methodological differences. In addition, there was no non-AKI
comparator group in any of the published studies. The cumulative incidence rates for proteinuria, hypertension, abnormal
GFR (<90 ml/min/1.73 m2), GFR < 60 ml/min/1.73 m2, end stage renal disease, and mortality per 100 patient-years were
3.1 (95% CI 2.1-4.1), 1.4 (0.9-2.1), 6.3 (5.1-7.5), 0.8 (0.4 -1.4), 0.9 (0.6-1.4), and 3.7 (2.8-4.5) respectively.
Conclusions: AKI appears to be associated with a high risk of long-term renal outcomes in children. These findings may
have implications for care after an episode of AKI in children. Future prospective studies with appropriate non-AKI
comparator groups will be required to confirm these results.
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Pediatric acute kidney injury (AKI) is a significant health
concern as its incidence has rapidly increased over the last
30 years [1,2]. The increased incidence of AKI dispropor-
tionately affects children with chronic medical diseases who
are hospitalized frequently and now living longer lives. This
represents a shift in the epidemiology of AKI, in which AKI
is now more often associated with complications of a child’s
medical or surgical hospitalization compared to primary* Correspondence: chirag.parikh@yale.edu
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article, unless otherwise stated.renal disease [3-7]. For hospitalized patients, AKI is inde-
pendently associated with increased mortality and length of
stay [8-11].
Until recently, AKI was considered a transient reversible
syndrome. This paradigm has been refuted by a multitude
of animal research and clinical studies. These studies sup-
port the hypothesis that an episode of AKI can cause per-
manent long-term kidney damage [12-14]. Animal studies
have shown that AKI can lead to an irreversible reduction in
peritubular capillaries causing hypoxia of renal parenchyma
[15]. Additional studies show that AKI triggers molecular
pathways that lead to prolonged cellular inflammation even
after serum creatinine returns to baseline [16]. This inflam-
mation contributes to fibrosis of the kidney and long-term
renal dysfunction.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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AKI causes renal inflammation and subsequent fibrosis
that may result in chronic dysfunction [17,18]. Depend-
ing on the severity of inflammation and the site of injury
within the kidney, the phenotype of chronic dysfunction
may be in the form of proteinuria, hypertension, chronic
kidney disease (CKD), or end stage renal disease (ESRD).
Multiple observational studies in adult populations have
shown that AKI is an independent risk factor for CKD,
ESRD, and mortality [19-25]. A systematic review and
meta-analysis by Coca et al. determined that the long-
term risk of CKD and ESRD in adult patients after AKI
is higher compared with patients without AKI, with haz-
ard ratios of 8.8 (95% CI 3.1-25.5) and 3.1 (95% CI 1.9-
5.0) respectively [20]. While this adult research is strik-
ing, it is not sufficient to understand whether AKI is an
independent risk factor for CKD in children. This is be-
cause CKD risk factors, such as diabetes, coronary artery
disease, hypertension, and smoking are more prevalent
in adults and influence the development of clinical out-
comes after AKI. In a way, the pediatric population is an
ideal group to study the actual contribution of AKI as
they have fewer of these CKD risk factors affecting out-
comes. Children also have a longer life expectancy with
a longer time to manifest some of the possible outcomes
after an episode of AKI.
It is important to understand the contribution of
pediatric AKI to long-term renal and non-renal out-
comes. This is imperative since there are no established
outpatient management guidelines after resolution of an
AKI episode. A recent editorial by Askenazi proposed
that after an AKI children should have follow-up within
1 month of hospital discharge, quarterly for two visits,
and then annually for two years [26]. If CKD or protein-
uria is identified, patients would then be followed every
1 to 12 months as dictated by the KDIGO CKD guide-
lines [27]. This frequency of follow-up in CKD patients
is dictated by GFR, albuminuria, underlying comorbid
conditions, disease state, and risk of progression [27].
Proper follow-up of pediatric AKI patients could allow
for earlier identification of renal outcomes and institut-
ing therapy to limit disease progression. This follow-up
will be critical as more children with chronic diseases
are living longer and developing multiple AKI episodes
over time [28,29]. The goal of the present study was to
conduct a systematic review of the published literature
and estimate the risk for long-term sequelae of renal and
non-renal outcomes after AKI.
Methods
We searched the MEDLINE and EMBASE databases
using the following terms: acute kidney injury (explode),
AKI, ARF, chronic renal insufficiency (explode), chronic
renal failure (explode), CKD, chronic disease, treatmentoutcome, follow-up studies, survival rate, quality of life,
kidney injuries, and acute disease (refer to the on-line
supplementary search strategy in Additional file 1 for a
list of the search terms used). We also searched SCO-
PUS and the reference list of all reviewed articles to
identify other eligible studies.
Studies were eligible for inclusion based upon the fol-
lowing criteria: 1) published from January 1985 onward; 2)
mean outpatient follow-up after the episode of AKI was
greater than 1 year; 3) pediatric cohort including patients
aged 0–18 years at the time of AKI; 4) estimated GFR or
measured GFR reported at a long-term follow-up visit.
Data on proteinuria, hypertension, ESRD, or mortality as
part of the follow-up data were also recorded. If a study
had multiple time points when long-term follow-up data
was obtained, the data from the last follow-up visit was
used. There was no language restriction. Each article
chosen by the primary reviewer was reviewed by a second
reviewer to confirm eligibility.
Studies were excluded if they reported on fewer than
10 patients at the time of follow-up. We also excluded
studies that exclusively focused on neonates or studies
that had a majority of patients with primary renal dis-
ease (e.g. hemolytic-uremic syndrome, post-infectious
acute glomerulonephritis).
Data abstraction
Data was extracted by using a standardized data extrac-
tion form. The reviewers extracted data about character-
istics of participants (number, age, and sex), clinical
setting, type of study (prospective versus retrospective),
dates of enrollment, definition of AKI, definition of
CKD, and rate of the outcomes (proteinuria, CKD,
hypertension, ESRD, mortality) in participants with AKI.
Methodological quality was assessed using the Cochrane
Collaboration risk of bias guidelines [30].
Outcome measures and statistical analysis
Primary outcome measures were long-term cumulative inci-
dence rate of proteinuria, hypertension, abnormal GFR
(<90 ml/min/1.73 m2), GFR < 60 ml/min/1.73 m2, end stage
renal disease, and mortality. Abnormal GFR was also used
as an outcome in addition to GFR < 60 ml/min/1.73 m2 be-
cause many studies used abnormal GFR as a primary out-
come without specifying the GFR of each patient.
For each clinical outcome the cumulative incidence rate
per 100 patient-years of follow-up was calculated. To de-
termine this rate we used the number of events as our nu-
merator and the number of patient-years of follow-up as
our denominator. If there was no outcome data on the
patients who were not enrolled from the original hospital-
ized cohort, we excluded these patients in our patient-
years calculation. We also reported the pooled incidence
of each outcome which designates the frequency of each
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rate and pooled incidence are weighted values.
Results
We identified 1934 citations from our MEDLINE and
EMBASE online search and excluded 1882 citations based
on the review of title and abstract. Full texts and reference
lists for 52 articles were examined and 10 studies were in-
cluded in the systematic review (Figure 1). The characteris-
tics of the 10 studies included are described in Table 1. All
of the primary studies reported on renal outcomes in chil-
dren after discharge from a hospitalization during which
they had an episode of AKI. All 10 studies were cohort stud-
ies and only one was conducted prospectively. Five of the
studies enrolled hospitalized children with any stage of AKI
and the other five only enrolled patients who required renal
replacement therapy (RRT). Two studies reported on out-
comes in AKI associated with cardiac surgery.
The 10 studies representing 8 different countries en-
rolled 346 patients. Six different definitions of AKI were
used (Table 2). 60% (range 17-100%) of patients were en-
rolled from the surviving hospitalized cohort. Three of
the primary studies excluded patients with pre-existing
renal disease and the other 7 studies did not mention
whether these patients were included or excluded. Long-
term follow-up was also variable and was conducted
from 2 years to 16 years after the episode of AKI, with a
mean time of follow-up of 6.5 years. The outcome defi-
nitions and method of assessment for each primary stud-
ies is listed in Table 3.
A mean of 44% (range 17-100%) of the patients in the
detailed follow-up cohort were acutely dialyzed for their
AKI episode. 9 studies reported on the acute inpatient
mortality of patients which averaged to 24% (range 9-
68%) of patients dying with their acute illness.
Proteinuria after AKI
The outcomes for each study are reviewed in Table 2.
Eight studies reported on proteinuria. Multiple definitionsFigure 1 Selection of studies.of proteinuria were used in the primary studies (Table 3).
Proteinuria was most commonly defined by a spot urine
albumin to urine creatinine ratio greater than or equal to
30 mg/g or 2+ protein on urine dipstick. The rate of pro-
teinuria was 3.1 per 100 person-years (95% CI 2.1-4.1) and
the pooled incidence was 13.2% (95% CI 8.9-17.5%).
Hypertension after AKI
Nine studies reported on hypertension. Hypertension was
most commonly defined as repeated systolic or diastolic
blood pressures greater than the 95th percentile for age,
gender, and height. The rate of hypertension after AKI
was 1.4 per 100 person-years (CI 0.9-2.1) and the pooled
incidence was 6.6% (CI 3.8-9.4%).
Decline in GFR after AKI
All of the ten studies reported on abnormal GFR. In 8 of
the 10 studies abnormal GFR was defined as a GFR <
90 ml/min/1.73 m2. Six different methods of estimating
GFR were used, with 6 studies using the Schwartz for-
mula (see Table 3) [31-35]. The rate of abnormal GFR
was 6.3 per 100 person-years (CI 5.1-7.5) and the pooled
incidence was 28.0% (CI 23.2-32.7%). Nine studies re-
ported on the number of patients who developed CKD
with a GFR < 60 ml/min/1.73 m2 after AKI, which was
0.8 per 100 person-years (CI 0.4-1.4) and the pooled in-
cidence was 3.6% (CI 1.5-5.7%). Eight studies reported
on ESRD at follow-up, which was 0.9 per 100 person-
years (CI 0.6-1.4) and the pooled incidence was 0.4% (CI
0–0.9%). The pooled rate of impaired GFR and ESRD
after AKI was 7.2 per 100 person-years.
Long-term mortality after AKI
Six studies reported on patients who had died after hospital
discharge. The cumulative incidence rate of mortality was
3.7 per 100 person-years (CI 2.8-4.5) and the pooled inci-
dence was 17.6% (CI 13.6-21.6%). As there was no com-
parator group within the studies, we compared long-term
mortality rates after AKI with mortality rates of other
Table 1 Characteristics of long-term follow-up studies of pediatric Acute Kidney Injury (AKI)
Author, Year published Country Site Study type Setting Severity Episode of AKI Age range of AKI Mean F/U(y) Mean age at F/U(y)
Askenazi [14], 2006 USA SC R Hospitalized Mixed AKI 1998 - 2001 6.4yσ 4 9.8
Buysse [50], 2008 Netherlands SC R Meningitis Mixed AKI 1988 - 2001 0.7-13.5y 10 15.9
Georgaki-Angelaki [45], 1989 U.K. SC R Hospitalized RRT 1971 - 1975 3d-10y 10 13
Mammen [41], 2012 Canada SC P Hospitalized Mixed AKI 2006 - 2008 0-18y 2* 3.0*
Mel [36], 2013 Israel SC R Cardiac surgery PD 1996 - 2004 0.12yσ 5* 8.4
Miler, 1997 Poland SC R Hospitalized Mixed AKI 1980 - 1990 3d-5y 6 -
Shaw [44], 1991 U.K. SC R Cardiac surgery RRT 1983 - 1988 2d - 2.5y 3 4.5
Slack [51], 2005 U.K. MC R Meningitis RRT 1996 - 1999 0.5-15y 4* 9.7
Viaud [46], 2011 France SC R Hospitalized RRT 1989 - 1996 1-14y 16* 21*
Wedekin [52], 2008 Germany SC R Hospitalized Infant Mixed AKI 1997 - 2003 0-1y 3* -
Abbreviations: PD, peritoneal dialysis, RRT, renal replacement therapy, SC, single center, MC, multi-center, R, retrospective, P, prospective, d, days, y, years, F/U, follow-up, Mixed AKI, encompasses all types of AKI: mild






























































40/425, (9) 17 33 2* … 126 GFR ≤90 39 1 0 10 3
Mel [36],
2013
RRT 35/76, (46) 100 61 5* 15/41, (37) 25 GFR <90 4 0 0 0 0
Miler, 1997 AKIΩ 28/118, (24) 34 67 6 4/64, (6) 60 GFR <90 46 6 0 … 3
Shaw [44],
1991
RRT 23/34, (68) 100 100 3 0/11, (0) 11 abnormal
mGFR
9 0 0 0 9
Slack [51],
2005
RRT 6/21, (29) 100 80 4* … 12 β GFR <90 25 8 0 17 25
Viaud [46],
2011
RRT 16/52, (30) 100 36 16* 0/36, (0) 13 GFR <90 61 23 0 54 15
Wedekin [52],
2008
SCr >1.1 26/70, (37) 17 100 3* 7/44 (16) 44 abnormal SCr 0 … … … …
The original hospitalized cohort is described along with the detailed follow-up cohort. The detailed follow-up cohort was assessed for long-term outcomes. Abbreviations: h, hour, RRT, renal replacement therapy, GFR,
glomerular filtration rate (ml/min/1.73 m2), SCr, serum creatinine (in mg/dl. 1 mg, HTN, hypertension, UOP, urine output, AKIN criteria, Acute Kidney Injury Network classification system: Δ SCr >0.3 mg/dL in 48 h, Δ SCr
≥50%, or UOP <0.5 ml/kg/hr X 6 h, Ω, AKI diagnosed by “generally accepted criteria”, F/U, follow-up, …,not available, β, only patients with abnormal SCr at PICU discharge were followed, Enrolled (%) = # of patients






























Askenazi [14], 2006 Urine alb/UCr ratio
> 30 mg/g
NS sys or dia >95% for age, sex, ht. HTN confirmed with
2 repeat visits
NS GFR <90 Schwartz formula
Buysse [50], 2008 UPr/UCr >0.2 mg/
mg
Avg of 3 first morning samples sys > 95% for age, sex, ht Avg of 3 BP
measurements




NS dipstick abnormal BP for age NS GFR <90 Inulin Clearance
Mammen [41], 2012 Urine alb/UCr
ratio ≥ 30 mg/g
Spot collection. If positive, first
morning sample
sys or dia >95% for age, sex, ht. HTN confirmed with
ABPM or 2 repeat visits
lowest of 3 BP
readings
GFR ≤90 Schwartz formula or
DTPA clearance
Mel [36], 2013 NS Urinalysis BP >90% NS GFR <90 Schwartz formula
Miler, 1997 NS NS NS NS GFR <90 Schwartz formula





Slack [51], 2005 >150 mg/day 24 hour collection sys >95% for age, sex, ht lowest of 3 BP
readings
GFR <90 EDTA clearance
Viaud [46], 2011 UPr/UCr >0.5 mg/
mg
NS NS NS GFR <90 EDTA clearance
Wedekin [52], 2008 NP NP NP NP abnormal SCr Schwartz formula
Abbreviations: Alb albumin, UCr urine creatinine, UPr urine protein, NS not specified, Avg average, NP not performed, sys systolic, dia diastolic, HTN hypertension, ht height, BP blood pressure, DTPA diethylenetriamine
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of patients evaluated three years after discharge from the
PICU, a meta-analysis of hemolytic uremic syndrome survi-
vors evaluated after a mean follow-up of 4.4 years, survivors
of Ewing sarcoma evaluated after 25 years, and the general
pediatric population mortality rate (Figure 2) [14,15,36-39].
The AKI long-term mortality rate depicted in Figure 2 was
comparable to the mortality rates found in other pediatric
cohorts, but higher than the mortality rate of the general
pediatric population [40]. Long-term event rates after AKI
are displayed in Figure 3.
Discussion
This is the first systematic review and meta-analysis
evaluating the long-term outcomes after pediatric AKI.
We calculated the cumulative incidence rates and pooled
incidence of long-term kidney complications such as
proteinuria, hypertension, abnormal GFR, CKD, and
ESRD after an episode of AKI. None of the studies in-
cluded a control group that would allow us to under-
stand the attributable risk of these complications thatFigure 2 Long-term mortality in various pediatric cohorts.would be related to AKI. The long-term risk of mortality
after AKI was also high when compared with the general
pediatric population. While some of the renal outcomes
may be attributed to the fact that these children are
sicker with many subsequent hospitalizations and co-
morbidities, it is likely that the episode of AKI itself is
associated with permanent renal damage and progressive
decline in kidney function.
As mentioned previously, experimental studies in ani-
mals describe several mechanisms by which AKI may
cause long-term sequelae, as it induces hypoxia, inflam-
mation, and fibrosis [12-16]. These studies suggest that
AKI may play a causal role in subsequent renal out-
comes. Multiple studies in adults have included control
groups and demonstrate that AKI is an independent risk
factor for renal outcomes [19-23]. The incidence rates of
renal outcomes estimated in the adult literature are
higher compared to our findings [20]. The systematic re-
view by Coca et al. reported rates of CKD, ESRD, and
mortality of 25.8 per 100 patient-years (range 3.4-72.2),
8.6 per 100 patient-years (range 0.63-28.1), and 16.8 per
Figure 3 Cumulative long-term rates of renal outcomes and mortality.
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This higher rate of outcomes in adults can be somewhat
attributed to the greater prevalence of comorbid risk
factors of ESRD such as CKD, diabetes, and heart failure
in the adult population. At the index hospitalization
approximately 1/3 of patients have CKD, 1/3 to ½ have
diabetes, and 1/3 have heart failure in the adult AKI
cohorts [19,21-23,25]. In addition, as we observed in
pediatric cohorts, the etiology of AKI in adults is most
commonly due to complications of a surgery or
hospitalization, not primary kidney disease. Despite the
tremendous growth of AKI clinical research over the
past decade, clinical studies in children and adults have
yet to establish that preventing an episode of AKI de-
creases the risk of development of CKD and premature
mortality.
One of the long-term outcomes evaluated in the primary
studies was a GFR between 60 and 90 ml/min/1.73 m2. In
this review we estimated that this outcome was almost
seven times more likely than a GFR <60 ml/min/1.73 m2.
The clinical significance of having a GFR between 60 and
90 ml/min/1.73 m2 comes into question especially when it
is estimated using the imprecise Schwartz formula. Use of
the new bedside CKiD equation would likely have differing
results as it has been shown to improve the accuracy of es-
timating GFR in children with CKD [31]. Even if an eGFR
of 60–90 ml/min/1.73 m2 represents a true defect in glom-
erular filtration after the AKI, it is unclear whether this is a
fixed abnormality of no clinical consequence or an abnor-
mality that will progress to CKD and ESRD. The limited
data from this review highlights this clinical uncertainty as
no increased rates of abnormal GFR were found with in-
creasing follow-up time. Moreover, it reinforces the need
for research with a longer length of follow-up. A longer
follow-up time will be beneficial, because even if it takes
25 years to manifest CKD after AKI, this would be clinicallymeaningful for a child who can have an additional 75 years
of life expectancy after their AKI.
Two of the primary studies included hyperfiltration, or
a GFR >150 ml/min/1.73 m2, as an outcome measure
[14,41]. We did not include hyperfiltration in our results
as this clinical parameter is not used to identify patients
at risk for CKD or diagnose CKD in clinical practice
guidelines such as Kidney Disease Improving Global
Outcomes (KDIGO) and Kidney Disease Outcomes
Quality Initiative (KDOQI) [27,42]. Hyperfiltration’s sig-
nificance as a marker of kidney dysfunction and a pre-
dictor of GFR decline after pediatric AKI is unclear and
has not been validated in a pediatric cohort [43].
The topic of long-term outcomes after pediatric AKI is
attracting more focus from the medical community as
children with chronic disease are living longer and pos-
sibly at risk for recurrent episodes of AKI. Although
there has been no systematic review performed on this
topic previously, a similar review and meta-analysis was
performed on children after hemolytic uremic syndrome.
Garg et al. studied long-term renal outcomes after
Hemolytic Uremic Syndrome and estimated that the rate
of GFR < 80 ml/min/1.73 m2 was 5.7 per 100 patient
years, ESRD was 0.7 per 100 patient years, and mortality
was 2.0 per 100 patient years [13]. In our systematic re-
view the rate of abnormal GFR was 6.3, ESRD was 0.9,
and mortality was 3.7 per 100 patient years.
While our review compels us to look closer at AKI as
a risk factor for CKD in children, there were certain lim-
itations to our results. First, 44% of patients included in
these follow-up studies required renal replacement ther-
apy during the index hospitalization for AKI. This is a
higher percentage than is typically encountered in a co-
hort of pediatric AKI patients. More patients with severe
AKI could have biased our results towards a higher cumu-
lative incidence rate of renal dysfunction. There were also
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studies with some studies including only patients who re-
quired dialysis and others including any patient that had a
0.3 mg/dL increase in serum creatinine. The substantial
difference between different AKI definitions could clearly
affect the results in individual studies. Unfortunately a
sensitivity analysis, where we stratified by AKI severity,
was not feasible due to the small number of primary stud-
ies. Furthermore, many of the primary studies did not dis-
tinguish pre-renal causes of AKI from renal causes,
including patients with any type of AKI and grouping
them together. An AKI from volume depletion with a
transient 0.3 mg/dl change in serum creatinine is less
likely to have long-term sequelae as compared with an
AKI from acute tubular necrosis. In order to definitively
validate the long-term effects of AKI, standard definitions
of AKI and CKD need to be uniformly adopted and used
consistently in long-term studies [27,42].
The primary studies included in this review have sub-
stantial differences of methodological quality with regards
to selection of patients, loss to follow-up, and reporting of
outcomes. We see that some studies report a high inci-
dence of CKD after AKI and others reported none. One of
the potential explanations for this variability is the differ-
ences in outcome definitions. The two studies by Shaw
et al. and Georgaki-Angelaki et al. found no evidence of
proteinuria using urine dipstick testing whereas studies by
Askenazi et al. and Mammen et al. found a much higher
incidence of proteinuria when using the more sensitive
test for microalbuminiuria [14,41,44,45]. On the other
hand, Viaud et al. used a higher threshold test of a urine
protein to creatinine ratio greater than 0.5 mg/mg to de-
fine proteinuria and found a 54% incidence [46]. This
higher proportion of proteinuria may be attributed to the
small sample size and a longer median follow-up time of
16 years. In addition, hypertension was diagnosed in some
studies at one office visit whereas others required three
separate visits for this diagnosis. Differing outcome defini-
tions and methods of ascertainment highlight the import-
ance of adhering to international consensus definitions
when designing clinical studies. Due to this inter-study
variability our pooled results should be interpreted
carefully.
Other limitations of this study include small sample
sizes and high rates of loss to follow-up. The latter may
have introduced attrition bias, as the sicker population
may be more likely to maintain contact with their physi-
cians. These sicker patients may have inflated our calcu-
lated outcomes and led us to overestimate the amount of
renal dysfunction after AKI.
With an increasing awareness of the long-term outcomes
after AKI, more research needs to be performed. It remains
to be determined whether all patients with AKI need to
monitored or just those with more severe or prolonged AKI.Monitoring for renal outcomes would be relatively simple,
likely involving a blood pressure check, a urine dip, and
a serum creatinine. CKD-related complications such as
proteinuria or hypertension could then be treated with a
renin-angiotensin-aldosterone antagonist such as an ACE-
inhibitor or an angiotensin receptor blocker. Primary care
providers will likely become more involved with CKD
screening as more children with chronic medical diseases
are surviving their AKI and living longer.
Conclusions
AKI appears to be associated with a higher risk of long-
term renal and non-renal outcomes in children as com-
pared with the general pediatric population. However, the
variation in renal outcomes between primary studies was
sufficiently large to advise caution before interpreting
these findings. Additional research will be needed to more
accurately calculate rates of long-term outcomes after
AKI. The different outcome definitions used by primary
studies underscore the importance of adhering to KDIGO
AKI and CKD guidelines when defining clinical outcomes
in future studies [27,47]. Future research should include
control groups where hospitalized patients without AKI
are followed for renal sequelae. The lack of control groups
in the primary studies clearly demonstrates a gap in the
literature. Ongoing prospective long-term follow-up
studies by the TRIBE-AKI (Translational Research In-
vestigating Biomarker End-Points) consortium and the
ASSESS-AKI Study (Assessment, Serial Evaluation, and
Subsequent Sequelae of Acute Kidney Injury) was designed
with control groups and should help to better define long-
term outcomes after AKI in children [48-52]. In addition,
there is a growing effort to study long-term AKI outcomes
in neonates which was a focus of the NIH-sponsored Neo-
natal Acute Kidney Injury Workshop on April 9, 2013. A
better understanding of pediatric AKI should provide op-
portunities for novel therapies and should direct the evolv-
ing guidelines of post-AKI outpatient management.
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